Condense Eli Lilly flashcards
Call Kai
Learn
Practice Test
Spaced Repetition
Match
Flashcards
Knowt Play1/63
There's no tags or description
Looks like no tags are added yet.
64 Terms
What does Eli Lilly do?
Lilly discovers and sells medicines across diabetes and obesity plus cancer and immunology and neuroscience. Most growth now comes from its GLP-1 franchise.
What are Lilly's three key obesity and diabetes products?
Mounjaro is injectable tirzepatide for type 2 diabetes. Zepbound is injectable tirzepatide for weight management and other approved uses. Foundayo is once-daily oral orforglipron for weight management in the US.
How dependent is Lilly on Mounjaro and Zepbound?
They generated about $16.1B in Q3 2026 or 66% of Lilly's $24.4B quarterly revenue. Great growth driver but major concentration risk.
What do GLP-1 and GIP and glucagon do?
GLP-1 helps regulate appetite and blood sugar. GIP supports glucose-dependent insulin signaling. Glucagon raises blood sugar and its receptor may also increase energy expenditure.
How do tirzepatide and semaglutide and orforglipron differ?
Tirzepatide activates GLP-1 and GIP and is Lilly's injectable. Semaglutide activates GLP-1 and is Novo's drug. Orforglipron activates GLP-1 and is Lilly's pill.
What is retatrutide and why is it important?
Lilly's experimental weekly triple agonist targets GLP-1 plus GIP plus glucagon. Strong Phase 3 results could extend its efficacy lead if approved.
How do weight-loss efficacy claims compare?
Retatrutide reached 28.3% average loss in one Phase 3 trial. Tirzepatide and semaglutide also show major reductions. Cross-trial percentages are not direct head-to-head proof.
What were Lilly's Q3 2026 earnings?
Revenue was $24.4B or +39% year over year. Reported EPS was $7.22 and non-GAAP EPS was $7.48. Results beat expectations.
What happened to volume and pricing in Q3 2026?
Lilly reported +53% worldwide sales volume and -15% realized pricing year over year. Revenue still grew 39%. Those figures are company sales drivers and not patient counts.
What is Lilly's latest 2026 guidance?
After Q3 management guided to $91B-$92B revenue and $35-$36 non-GAAP EPS. EPS includes acquisition-related research charges.
Why scrutinize the quality of Lilly's Q3 earnings?
Revenue included about $900M of favorable items including $410M of Jardiance milestones and rebate adjustments. Not all quarterly growth will recur.
Why is the obesity-drug market potentially much larger?
Many people meet treatment criteria but do not take medication. Affordability plus coverage plus pills plus international launches could grow the treated population.
What prevents eligible patients from using GLP-1 drugs?
High out-of-pocket cost and limited coverage plus side effects and treatment discontinuation and injection aversion. Eligibility does not guarantee access or demand.
Why does patient persistence matter?
Many people stop treatment because of cost or tolerability or other factors. Sustained use affects lifetime revenue per patient more than a single new prescription.
How can lower drug prices still increase Lilly revenue?
More affordable treatment can increase prescription volume enough to outweigh lower net revenue per prescription. The critical test is the actual change in both.
What happens if price falls 20% and volume rises 10%?
Revenue falls about 12% because 0.80 times 1.10 equals 0.88. Volume growth does not automatically offset pricing pressure.
What does Medicare GLP-1 access mean for Lilly?
The Medicare GLP-1 Bridge gives eligible beneficiaries certain drugs for $50 monthly from July 2026 through December 2027. It could grow volume while adding reimbursement pressure.
Why does the November 2026 Hims and Hers agreement matter?
Eligible Hims users can obtain FDA-approved Foundayo or Zepbound at Lilly self-pay prices. It adds distribution and convenience but does not guarantee extra demand.
Why is Foundayo strategically important?
Its daily pill has no fasting or water restrictions. It may attract injection-averse patients and broaden treatment access rather than only cannibalize Zepbound.
How strong was Foundayo's Q3 2026 launch?
Foundayo booked $184M in sales against Lilly's $24.4B total. Adoption is important but the near-term Lilly thesis is still dominated by tirzepatide.
Who is Lilly's biggest direct competitor?
Novo Nordisk. Ozempic and Wegovy compete with Mounjaro and Zepbound while oral Wegovy competes with Foundayo. Novo is already commercially established.
What happened in Novo's February 2026 CagriSema trial?
CagriSema produced 23.0% weight loss versus 25.5% for tirzepatide at 84 weeks in REDEFINE 4. It failed to show non-inferiority to tirzepatide.
Which emerging competitors should Lilly monitor?
Amgen's MariTide and Roche's obesity pipeline and Pfizer's obesity programs and Viking's VK2735. Most are pipeline threats rather than proven commercial rivals.
What determines who wins the GLP-1 market?
Efficacy and safety plus convenience and net pricing plus insurance access and manufacturing capacity and real-world patient retention.
What products diversify Lilly beyond GLP-1 drugs?
Verzenio and Jaypirca in cancer plus Kisunla in Alzheimer's and Ebglyss and Omvoh in immunology. Diversification matters but obesity still drives most growth.
What did Foundayo's November 9 sleep-apnea study show?
Foundayo reduced sleep-apnea events by 43.8% at 52 weeks among patients not using PAP therapy. Lilly plans to seek US approval for this use by end-2026.
When could retatrutide reach regulators?
Retatrutide is not approved. Lilly targets a US FDA submission in Q1 2027 after positive Phase 3 studies. Any approval date remains uncertain.
Why is manufacturing expansion a competitive advantage?
More capacity could reduce shortages and support new drug launches. The cost is higher near-term capital spending and risk of overbuilding.
What FDA risk could most damage Lilly?
A serious new safety finding or label restriction that reduces eligibility or prescriptions for tirzepatide. Familiar GI adverse effects already affect tolerability.
How expensive was LLY in November 2026?
On November 11 valuation was roughly 30-31 times forward EPS and 46-47 times trailing EPS with price-to-sales near 15 times. These multiples change daily.
What is forward P/E versus trailing P/E?
Trailing P/E compares share price with the last 12 months of earnings. Forward P/E uses expected future earnings. A lower forward multiple suggests forecast EPS growth.
How does Lilly's valuation compare with Novo?
Lilly trades at a much higher forward P/E than Novo at roughly 30 versus 12 times in early November 2026. The premium requires faster and more durable earnings growth.
What earnings growth is already expected?
Selected November 2026 consensus estimates put revenue near $107B in 2027 and $141B in 2030 with EPS near $50 and $72. Longer-term estimates are less certain.
Why is obesity-market growth alone not a buy thesis?
Investors already expect large growth. A good pitch explains why Lilly's earnings or durability should exceed the assumptions embedded in its stock price.
Why could Lilly's P/E fall even as earnings rise?
Investors may assign a lower multiple as growth slows or competition rises. Earnings growth and multiple contraction can happen together.
What is the simplest stock-price valuation equation?
Projected EPS times an assumed P/E multiple equals an illustrative price target. Both assumptions need a reason and a sensitivity check.
What is the central bull case for Lilly?
More treatment access and patient volumes could outweigh lower prices. Foundayo and retatrutide and new indications offer extra growth beyond consensus expectations.
What is the central bear case for Lilly?
A rich valuation leaves little room for setbacks. Pricing pressure or stronger competitors or weak pill adoption or pipeline failures could hurt earnings and compress the P/E.
What specifically might Wall Street underestimate?
The pace of sustained patient adoption and international access plus new indications and better manufacturing productivity. These are hypotheses to test against consensus estimates.
What would make you change the bullish thesis?
Persistent volume growth below pricing declines or significant loss of market share or major safety restrictions or repeated earnings misses. Reassess fair value rather than react to one price drop.
What are Lilly's six biggest upcoming catalysts?
Dec 7 Innovation Day and Q4 CagriSema decision plus Foundayo FDA milestones and weekly GLP-1 access trends plus early-2027 earnings and Q1 retatrutide filing. Some dates are unconfirmed.
What would you monitor weekly before earnings?
Prescription share and net pricing plus payer coverage and Novo updates and analyst EPS revisions. Watch sustained trends rather than one noisy week.
How do interest rates and risk appetite affect LLY?
Higher rates or weaker risk appetite can reduce the P/E investors pay for future profits. Lilly is a defensive healthcare name but also an expensive growth stock.
What is Lilly actually doing with NVIDIA and AI?
In January 2026 Lilly and NVIDIA announced up to $1B of joint investment over five years in an AI co-innovation lab for drug discovery and manufacturing research.
What is Lilly's AI supercomputer opportunity?
Lilly is building compute infrastructure for biomedical models that may screen and optimize molecules earlier. Potential benefit is better R&D productivity rather than immediate drug sales.
Why could TuneLab become an unusual AI moat?
TuneLab gives biotech partners access to Lilly-trained discovery models built using proprietary research data. Partner contributions could expand training data and strengthen the models.
How could AI improve Lilly's manufacturing economics?
Robotics and digital twins could model production lines and reduce bottlenecks or waste. If proven at scale this could improve output and margins on high-demand drugs.
How could AI improve Lilly's clinical trials?
AI might improve patient recruitment and trial design or identify likely failures earlier. Replacing control groups would still need scientific validation and regulatory acceptance.
What AI advantage could the market underappreciate?
If Lilly's proprietary data plus compute plus partner feedback improve drug-discovery success or factory productivity then future margins and pipeline value may exceed consensus. This is unproven.
Why should AI not be a near-term earnings centerpiece?
Discovery candidates still require clinical testing and FDA review. AI spending is real now while revenue and margin benefits may take years and could be competed away.
What evidence would validate the AI bull case?
More candidates reaching trials with better success rates plus shorter cycle times and measurable manufacturing yield or cost improvements versus peers and Lilly's own history.
How do Lilly's AI investments fit the stock thesis?
They create long-term upside optionality beyond GLP-1s. Pitch confirmed partnerships and plausible mechanisms but never call AI profits guaranteed or definitely unpriced.
What if Novo is much cheaper than Lilly?
Novo offers a lower valuation but may have weaker expected growth. Lilly must deliver enough incremental EPS and competitive durability to justify paying the premium.
Why might now be a catalyst-rich time to pitch Lilly?
Innovation Day and near-term competitor FDA decisions and 2027 guidance and retatrutide submission could change growth expectations. Good news alone is not enough if already priced in.
How should you defend a price target?
State forecast EPS and target multiple and time horizon. Explain how those differ from consensus and show what happens if growth slows or the multiple contracts.
What is an illustrative 2030 Lilly valuation range?
Bear $60 EPS times 18 equals $1080. Base $72 times 23 equals $1656. Bull $90 times 25 equals $2250. These are assumptions rather than analyst price targets.
What is the biggest risk in a bullish Lilly valuation?
Earnings disappoint at the same time investors reduce the valuation multiple. The stock could fall even if absolute revenue keeps increasing.
What is the one-sentence thesis test for Lilly?
My thesis depends on Lilly growing patient volumes faster than prices decline while maintaining its competitive advantage. If that relationship breaks down consistently I would reassess my valuation and investment recommendation.
How would you explain Lilly in 30 seconds to a non-expert?
Lilly makes major diabetes and weight-loss medicines. The opportunity is treating many more eligible patients through access and pills while new drugs and technology could extend its growth. The key risk is paying too much for that future.
What is the most important interview distinction?
A great company is not necessarily a great stock at any price. Explain where your forecast exceeds consensus and why that upside exceeds the downside risk.
7 step pitch
1) Company in 1 sentence. What do they do?
2) Thesis. Why Lilly? Why Today?
3) Supporting evidence. 3 pieces of evidence supporting the thesis
4) What is the stock worth and how did I calculate that
5) Catalysts. Upcoming events that will force the stock price to move
6) Risks. What could break thesis
7) Recomendation and target. Buy - and at what price?
<1 = undervalued
1 = fair price
>1 overvalued